- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts
U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
452
Companies which are more than 50% undervalued based on analyst price target.
452 companies
Phio Pharmaceuticals
Market Cap: US$14.2m
A a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States.
PHIO
US$2.42
7D
8.5%
1Y
-23.9%
BiomX
Market Cap: US$13.9m
A clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases.
PHGE
US$0.47
7D
-10.4%
1Y
-50.9%
BioCardia
Market Cap: US$13.7m
A clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States.
BCDA
US$1.33
7D
-10.1%
1Y
-51.8%
Chemomab Therapeutics
Market Cap: US$13.6m
A clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States.
CMMB
US$2.64
7D
1.5%
1Y
-56.3%
Imunon
Market Cap: US$12.9m
A clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines.
IMNN
US$5.25
7D
2.3%
1Y
-59.7%
GeoVax Labs
Market Cap: US$12.0m
A clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States.
GOVX
US$0.54
7D
-17.1%
1Y
-74.6%
Sensei Biotherapeutics
Market Cap: US$11.9m
A clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients.
SNSE
US$9.80
7D
8.6%
1Y
-3.9%
Intensity Therapeutics
Market Cap: US$11.9m
A late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States.
INTS
US$0.26
7D
3.1%
1Y
-93.1%
BioRestorative Therapies
Market Cap: US$11.6m
Develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
BRTX
US$1.43
7D
-1.4%
1Y
-10.1%
Marker Therapeutics
Market Cap: US$11.5m
A clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
MRKR
US$0.91
7D
-0.7%
1Y
-64.9%
Carisma Therapeutics
Market Cap: US$11.4m
A biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States.
CARM
US$0.26
7D
-9.2%
1Y
-73.5%
cbdMD
Market Cap: US$10.8m
Produces and distributes various cannabidiol (CBD) products in the United States.
YCBD
US$1.14
7D
70.5%
1Y
-68.4%
KALA BIO
Market Cap: US$10.7m
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases.
KALA
US$1.36
7D
-92.9%
1Y
-74.8%
Lyra Therapeutics
Market Cap: US$10.7m
A clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis.
LYRA
US$6.57
7D
1.1%
1Y
-46.4%
Biofrontera
Market Cap: US$10.5m
A biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
BFRI
US$1.02
7D
6.3%
1Y
-4.7%
Evoke Pharma
Market Cap: US$10.4m
Operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
EVOK
US$4.66
7D
-7.9%
1Y
-5.9%
Bolt Biotherapeutics
Market Cap: US$10.2m
A clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer.
BOLT
US$5.66
7D
-1.9%
1Y
-56.2%
IN8bio
Market Cap: US$9.9m
A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases.
INAB
US$2.26
7D
8.1%
1Y
-71.4%
Processa Pharmaceuticals
Market Cap: US$9.7m
A clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment.
PCSA
US$0.20
7D
-5.8%
1Y
-85.1%
Kiora Pharmaceuticals
Market Cap: US$9.5m
A clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases.
KPRX
US$2.83
7D
7.6%
1Y
-22.0%
AEON Biopharma
Market Cap: US$9.4m
A clinical stage biopharmaceutical company, focuses on developing botulinum toxins.
AEON
US$0.80
7D
2.2%
1Y
-99.0%
Creative Medical Technology Holdings
Market Cap: US$8.6m
A commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.
CELZ
US$3.34
7D
7.4%
1Y
12.8%
Aprea Therapeutics
Market Cap: US$8.6m
A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
APRE
US$1.46
7D
2.8%
1Y
-46.0%
VYNE Therapeutics
Market Cap: US$8.5m
A clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions.
VYNE
US$0.34
7D
5.0%
1Y
-82.1%
Kazia Therapeutics
Market Cap: US$8.1m
Operates as an oncology-focused biotechnology company in South Korea.
KZIA
US$6.85
7D
-13.1%
1Y
-68.6%
HCW Biologics
Market Cap: US$8.0m
A clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States.
HCWB
US$3.82
7D
-7.7%
1Y
-80.2%
Palisade Bio
Market Cap: US$7.8m
A clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.
PALI
US$1.31
7D
91.4%
1Y
-61.5%
Adial Pharmaceuticals
Market Cap: US$7.7m
A clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.
ADIL
US$0.37
7D
6.5%
1Y
-61.0%
Alzamend Neuro
Market Cap: US$7.5m
A clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.
ALZN
US$2.45
7D
2.9%
1Y
-83.7%
Brainstorm Cell Therapeutics
Market Cap: US$7.3m
A biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases.
BCLI
US$0.71
7D
1.9%
1Y
-73.0%
Ensysce Biosciences
Market Cap: US$7.0m
A clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States.
ENSC
US$2.43
7D
9.0%
1Y
-30.9%
Sunshine Biopharma
Market Cap: US$6.8m
Operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada.
SBFM
US$1.54
7D
-1.3%
1Y
-47.4%
Acurx Pharmaceuticals
Market Cap: US$6.5m
A clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States.
ACXP
US$4.60
7D
10.8%
1Y
-89.3%
Sonoma Pharmaceuticals
Market Cap: US$6.4m
Develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally.
SNOA
US$3.86
7D
-5.4%
1Y
31.3%
CERo Therapeutics Holdings
Market Cap: US$6.1m
An immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
CERO
US$5.45
7D
0.4%
1Y
-96.9%
Calidi Biotherapeutics
Market Cap: US$6.1m
A clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States.
CLDI
US$1.63
7D
5.2%
1Y
-87.7%